Vera Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$401.9MTTM through 30 Jun 2026
Free Cash Flow -$338.9MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-24.2%ROE
-75.4%ROA
Balance Sheet Health
Debt / Equity0.15x
Current Ratio13.64x
Net Debt-$521.7Mnet cash position
Cash & Equivalents$48.9M
Quality Metrics
Altman Z-Score8.42
Piotroski F-Score1 / 9
Earnings-Beat Rate0.0%
Multi-Year Trend
Diluted EPS-$5.87TTMFY2025: $-4.66
Dividend
No dividend
Capital Allocation
R&D Spend$261.9M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Immunological Diseases Development | $0 | View detailsVera operates in a single reportable segment focused on developing and commercializing treatments for serious immunological diseases. Near-term outlook is highly dependent on the potential FDA approval and mid-2026 commercial launch of atacicept. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.